When every pharmaceutical company is chasing opportunities that will address high unmet medical needs, obtain commercial success, and speed to market, the competition is intense. Making well-informed and impactful decisions is paramount.
That’s why we developed AssetNav, a tool in the InizioNavigator.ai suite, that our consulting team utilizes to help inform critical clinical investment and BD&L decisions. It uses the power of AI and machine learning to help prioritize pipeline assets; in turn, this helps our consultants support clients’ decisions on how to prioritize their resources and powers our strategic recommendations.
In this blog, we explore two instances where our consulting teams used AssetNav to help clients prioritize promising BD&L opportunities in oncology.
The Role of AssetNav: A Data-Driven Foundation for Success
AssetNav is more than our internal proprietary tool; it’s a critical asset in our arsenal that transforms how we explore opportunities for clients. At its core, AssetNav aggregates and synthesizes vast amounts of data from over a dozen reliable sources, encompassing more than 50 disease areas, 3,000 mechanisms of action, 33,000 assets, and 20,000 trials. This breadth and depth of data provide the foundational intelligence needed to start our analysis on solid ground.
For instance, when a major biopharma client sought to explore partnering opportunities within gastrointestinal (GI) cancers, AssetNav enabled us to create a comprehensive list of ~150 targets. We then applied a series of highly specific filters to narrow down this list to the top 10 most commercially viable and scientifically promising targets. By leveraging AssetNav, our team then prioritized the 5-7 most actionable assets and developed target profiles and business cases. This process, which might have taken weeks if done manually, was completed in a fraction of the time, allowing our team to shift their focus to deeper strategic analysis.
People at the Helm: Strategic Insight Beyond the Data
One of our clients’ most significant challenges is the sheer volume of data that needs to be analyzed and synthesized during decision-making. AssetNav addresses these pain points by automating the initial data gathering and analysis stages, allowing our team to focus on higher-order strategic thinking.
While AssetNav is incredibly powerful, it is our people’s expertise that unlocks its potential. Our client’s confidence in their decisions is not just due to the data itself but also how we interpret and apply it. We actively collaborate with clients to define the right parameters and filters, ensuring that the insights align directly with their strategic goals.
For example, in a recent due diligence project focused on emerging therapies in oncology, our team used AssetNav to map out key trends across various cancer types. However, our strategic application of this data – considering factors like market timing, patient demographics, and competitive positioning – provided the client with actionable insights. The result was a set of well-vetted opportunities, ready for further exploration; the client had confidence in their investment decision.
The Strategic Edge: Advice for Leveraging AI in Decision-Making
For any organization looking to enhance its decision-making process with AI-powered tools, it’s crucial to remember that the real value comes from combining tools like AssetNav with deep industry expertise and strategic thinking. AI can handle data at scale, but people turn that data into actionable insights that drive meaningful business outcomes.
At Putnam, we partner closely with our clients to ensure that every project is tailored to specific needs and strategic objectives – helping to navigate the complexities of the pharmaceutical landscape and capitalize on opportunities that others might miss.
This dual approach – leveraging AI for efficiency, and human expertise for insight – ensures that our clients are not just making decisions faster but making the right decisions. They can move forward with the confidence that they’ve considered all relevant factors, from clinical data to market dynamics, before committing significant resources.
